Santaris Pharma and miRagen Therapeutics have formed a strategic alliance to develop microRNA-targeted medicines to treat deadly cardiovascular diseases.
MicroRNAs are thought of as the master regulators of gene expression, and clinical studies have linked them with many disease processes – making them potential drug targets for treating many conditions.
Through the alliance, miRagen is planning to develop and commercialise single-stranded locked nucleic acid (LNA)-based product candidates to treat cardiovascular diseases, using Santaris Pharma’s proprietary LNA drug platform.
In return, Santaris Pharma has received a minority equity interest in miRagen, and is eligible to receive payments and royalties when certain development and regulatory milestones are met.
Financial terms of the collaboration were not disclosed.